Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Previous issues

Page Path
HOME > Browse articles > Previous issues
17 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 14(1); January 2016
Prev issue Next issue
Perspective
A new start for 'Intestinal Research' as an official journal of AOCC
Toshifumi Hibi
Intest Res 2016;14(1):1-1.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.1
PDFPubReaderePub
  • 4,008 View
  • 34 Download
Close layer
Editorial
Are there interregional differences in the epidemiology and clinical characteristics of Crohn's disease in the Asia-Pacific region?
Sinwon Lee, Byong Duk Ye
Intest Res 2016;14(1):2-4.   Published online January 25, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.2
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Astragalin Inhibits Nuclear Factor-κB Signaling in Human Colonic Epithelial Cells and Attenuates Experimental Colitis in Mice
    Yoo Min Han, Jaemoon Koh, Jee Hyun Kim, Jooyoung Lee, Jong Pil Im, Joo Sung Kim
    Gut and Liver.2021; 15(1): 100.     CrossRef
  • 4,313 View
  • 41 Download
  • 3 Web of Science
  • 1 Crossref
Close layer
Reviews
Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?
Jun Kato, Sakiko Hiraoka, Asuka Nakarai, Shiho Takashima, Toshihiro Inokuchi, Masao Ichinose
Intest Res 2016;14(1):5-14.   Published online January 25, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.5
AbstractAbstract PDFPubReaderePub

Accurate evaluation of disease activity is essential for choosing an appropriate treatment and follow-up plan for patients with inflammatory bowel disease (IBD). Endoscopy is required for accurately evaluating disease activity, but the procedures are sometimes invasive and burdensome to patients. Therefore, alternative non-invasive methods for evaluating or predicting disease activity including mucosal status are desirable. Fecal calprotectin (Fcal) is the most widely used fecal marker for IBD, and many articles have described the performance of the marker in predicting disease activity, mucosal healing (MH), treatment efficacy, and risk of relapse. Fecal immunochemical test (FIT) can quantify the concentration of hemoglobin in stool and was originally used for the screening of colorectal cancer. We recently reported that FIT is also a useful biomarker for IBD. A direct comparison between the use of Fcal and FIT showed that both methods predicted MH in ulcerative colitis equally well. However, in the case of Crohn's disease, FIT was less sensitive to lesions in the small intestine, compared to Fcal. FIT holds several advantages over Fcal in regards to user-friendliness, including a lower cost, easy and clean handling, and the ability to make rapid measurements by using an automated measurement system. However, there is insufficient data to support the application of FIT in IBD. Further studies into the use of FIT for evaluating the inflammatory status of IBD are warranted.

Citations

Citations to this article as recorded by  
  • The synergy of dual faecal immunochemical and faecal calprotectin testing for accurate assessment of endoscopic and histological activity in inflammatory bowel disease
    Anuj Bohra, Nicholas Batt, Krishneel Dutt, Diana Lewis, Jonathan P. Segal, Olga Newiadomski, Abhinav Vasudevan, Daniel R. Van Langenberg
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • Biomarkers in inflammatory bowel disease: a practical guide
    Jennie Clough, Michael Colwill, Andrew Poullis, Richard Pollok, Kamal Patel, Sailish Honap
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • Multimodal Ultrasound Technology Combined with Fecal Calprotectin Assessment in Clinical Studies of Inflammatory Bowel Disease
    泊辛 陈
    Advances in Clinical Medicine.2024; 14(07): 1110.     CrossRef
  • Unraveling the intricacies of neutrophil extracellular traps in inflammatory bowel disease: Pathways, biomarkers, and promising therapies
    Yilin Wu, Jun Shen
    Cytokine & Growth Factor Reviews.2024; 80: 156.     CrossRef
  • Delivery of Encapsulated Intelligent Engineered Probiotic for Inflammatory Bowel Disease Therapy
    Zhen‐Ping Zou, Zhihao Cai, Xiao‐Peng Zhang, Donghui Zhang, Chu‐Ying Xu, Ying Zhou, Runhui Liu, Bang‐Ce Ye
    Advanced Healthcare Materials.2024;[Epub]     CrossRef
  • Positive Results from the Fecal Immunochemical Test Can Be Related to Dementia: A Nationwide Population-Based Study in South Korea
    Yu Kyung Jun, Seung Woo Lee, Kwang Woo Kim, Jung Min Moon, Seong-Joon Koh, Hyun Jung Lee, Joo Sung Kim, Kyungdo Han, Jong Pil Im
    Journal of Alzheimer's Disease.2023; 91(4): 1515.     CrossRef
  • Fecal immunochemical test for haemoglobin versus fecal calprotectin to monitoring endoscopic activity in inflammatory bowel disease
    Patricia Latorre Añó, Jorge Torrente Sánchez, Amparo Almudena Pérez Ibañez, Jose María Tenias Burillo, Nadia Paloma Moreno Sánchez, Antonio López-Serrano, Eduardo Moreno Osset, Julián Murado Pardo, José María Paredes
    Revista Española de Enfermedades Digestivas.2023;[Epub]     CrossRef
  • Tumorigenesis in Inflammatory Bowel Disease: Microbiota-Environment Interconnections
    Irene Mignini, Maria Elena Ainora, Silvino Di Francesco, Linda Galasso, Antonio Gasbarrini, Maria Assunta Zocco
    Cancers.2023; 15(12): 3200.     CrossRef
  • Propensity score analysis the clinical characteristics of active distal and extensive ulcerative colitis: a retrospective study
    Changchang Ge, Zhaofeng Shen, Yi Lu, Xiaojuan Liu, Yiheng Tong, Mengyuan Zhang, Yijing Liu, Hong Shen, Lei Zhu
    Frontiers in Physiology.2023;[Epub]     CrossRef
  • A unicentric cross-sectional observational study on chronic intestinal inflammation in total colonic aganglionosis: beware of an underestimated condition
    M Erculiani, F Poluzzi, G Mottadelli, E Felici, Novi ML, M Caraccia, A Grandi, S Casella, L Giacometti, G Montobbio, I Ceccherini, E Di Marco, C Bonaretti, R Biassoni, M Squillario, A Pietrantoni, V Villanacci, A Pini Prato
    Orphanet Journal of Rare Diseases.2023;[Epub]     CrossRef
  • Fecal miR‐223 is a noninvasive biomarker for estimating Crohn's disease activity
    Juanjuan Zhang, Zhen Guo, Zhiming Wang, Weiming Zhu, Qiurong Li
    Immunity, Inflammation and Disease.2023;[Epub]     CrossRef
  • Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis
    Changchang Ge, Yi Lu, Hong Shen, Lei Zhu
    Scandinavian Journal of Gastroenterology.2022; 57(5): 513.     CrossRef
  • Efficacy of Fecal Calprotectin Combined With Stool Hemoglobin in Differentiating Bacterial Origin in Acute Gastroenteritis
    Hyun Jin Kim
    Pediatric Emergency Care.2022; 38(2): e670.     CrossRef
  • Colorectal Cancer Screening in Inflammatory Bowel Diseases—Can Characterization of GI Microbiome Signatures Enhance Neoplasia Detection?
    Molly Pratt, Jessica D. Forbes, Natalie C. Knox, Gary Van Domselaar, Charles N. Bernstein
    Gastroenterology.2022; 162(5): 1409.     CrossRef
  • Occult Blood in Feces Is Associated with Increased Risk of Psoriasis
    Hyun Jung Lee, Kyungdo Han, Hosim Soh, Seong-Joon Koh, Jong Pil Im, Joo Sung Kim, Hyo Eun Park, Miri Kim
    Dermatology.2022; 238(3): 571.     CrossRef
  • Analytical evaluation of four faecal immunochemistry tests for haemoglobin
    Carolyn Piggott, Magdalen R. R. Carroll, Cerin John, Shane O’Driscoll, Sally C. Benton
    Clinical Chemistry and Laboratory Medicine (CCLM).2021; 59(1): 173.     CrossRef
  • Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review
    Monica State, Lucian Negreanu, Theodor Voiosu, Andrei Voiosu, Paul Balanescu, Radu Bogdan Mateescu
    World Journal of Gastroenterology.2021; 27(16): 1828.     CrossRef
  • Cost effectiveness of using Faecal Immunochemical Testing (FIT) as an initial diagnostic investigation for patients with lower gastrointestinal symptoms suggestive of malignancy
    CC Kearsey, C Graham, HS Lobb, J Chacko, R Weatherburn, PS Rooney
    BMC Family Practice.2021;[Epub]     CrossRef
  • Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis
    Natsuki Ishida, Satoru Takahashi, Yusuke Asai, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
    Immuno.2021; 1(4): 360.     CrossRef
  • Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    Bing-Jie Xiang, Min Jiang, Ming-Jun Sun, Cong Dai
    Visceral Medicine.2021; 37(5): 338.     CrossRef
  • Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease
    Kohei Wagatsuma, Yoshihiro Yokoyama, Hiroshi Nakase
    Life.2021; 11(12): 1375.     CrossRef
  • Fecal calprotectin predicts complete mucosal healing in patients with ulcerative colitis: Systematic review and meta‑analysis
    Zhongsheng Cao, Chenglong Ye, Lunan Li, Xiaoge Geng, Wensheng Pan, Jiyong Jing
    World Academy of Sciences Journal.2021;[Epub]     CrossRef
  • Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study
    Eun Soo Kim, Hyun Seok Lee, Sung Kook Kim, Eun Young Kim, Byung Ik Jang, Kyeong Ok Kim, Chang Heon Yang, Yoo Jin Lee
    Scandinavian Journal of Gastroenterology.2020; 55(2): 163.     CrossRef
  • Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease
    Jack S. Cornish, Elisa Wirthgen, Jan Däbritz
    Frontiers in Medicine.2020;[Epub]     CrossRef
  • Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker
    Natsuki Ishida, Takahiro Miyazu, Tomoharu Matsuura, Ryosuke Takano, Satoshi Tamura, Takuma Kagami, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
    International Journal of Colorectal Disease.2020; 35(9): 1729.     CrossRef
  • Fecal MicroRNAs as Potential Biomarkers for Screening and Diagnosis of Intestinal Diseases
    Humaira Rashid, Biplob Hossain, Towfida Siddiqua, Mamun Kabir, Zannatun Noor, Mamun Ahmed, Rashidul Haque
    Frontiers in Molecular Biosciences.2020;[Epub]     CrossRef
  • The association between fecal hemoglobin concentration and oral potentially malignant disorders
    Amy Ming‐Fang Yen, Sen‐Te Wang, Sheng‐Wei Feng, Che‐Tong Lin, Sam Li‐Sheng Chen
    Oral Diseases.2019; 25(1): 108.     CrossRef
  • Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review
    Joel Petit, Georgia Carroll, Tiffany Gould, Peter Pockney, Matthew Dun, Rodney J. Scott
    Journal of Surgical Research.2019; 236: 184.     CrossRef
  • Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations
    Emilio J. Laserna-Mendieta, Alfredo J. Lucendo
    Clinical Chemistry and Laboratory Medicine (CCLM).2019; 57(9): 1295.     CrossRef
  • Systematic Review with Meta-Analysis: Fecal Calprotectin as a Surrogate Marker for Predicting Relapse in Adults with Ulcerative Colitis
    Jiajia Li, Xiaojing Zhao, Xueting Li, Meijiao Lu, Hongjie Zhang
    Mediators of Inflammation.2019; 2019: 1.     CrossRef
  • Predictors of mucosal healing during induction therapy in patients with acute moderate‐to‐severe ulcerative colitis
    Maiko Motobayashi, Katsuyoshi Matsuoka, Kento Takenaka, Toshimitsu Fujii, Masakazu Nagahori, Kazuo Ohtsuka, Fumihiko Iwamoto, Kiichiro Tsuchiya, Mariko Negi, Yoshinobu Eishi, Mamoru Watanabe
    Journal of Gastroenterology and Hepatology.2019; 34(6): 1004.     CrossRef
  • Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis
    Dae Gon Ryu, Hyung Wook Kim, Su Bum Park, Dae Hwan Kang, Cheol Woong Choi, Su Jin Kim, Hyeong Seok Nam
    Medicine.2019; 98(36): e17080.     CrossRef
  • Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta‐analysis
    Cong Dai, Min Jiang, Ming‐Jun Sun, Qin Cao
    Journal of Gastroenterology and Hepatology.2018; 33(5): 990.     CrossRef
  • Monitoring Disease Activity: How and When?
    Kang-Moon Lee
    The Korean Journal of Gastroenterology.2018; 71(2): 69.     CrossRef
  • An assessment of the effect of haemoglobin variants on detection by faecal immunochemical tests
    Magdalen RR Carroll, Cerin John, Debbie Mantio, Natasha K Djedovic, Sally C Benton
    Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2018; 55(6): 706.     CrossRef
  • Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis
    Sakiko Hiraoka, Toshihiro Inokuchi, Asuka Nakarai, Shiho Takashima, Daisuke Takei, Yuusaku Sugihara, Masahiro Takahara, Keita Harada, Hiroyuki Okada, Jun Kato
    Gut and Liver.2018; 12(2): 142.     CrossRef
  • Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse
    Asuka Nakarai, Sakiko Hiraoka, Sakuma Takahashi, Tomoki Inaba, Reiji Higashi, Motowo Mizuno, Shiho Takashima, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Keita Harada, Jun Kato, Hiroyuki Okada
    Journal of Crohn's and Colitis.2018; 12(1): 71.     CrossRef
  • Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores
    Hai Yun Shi, Francis K. L Chan, Anthony W. H Chan, Akira Higashimori, Moe Kyaw, Jessica Y. L Ching, Arthur K. C Luk, Sunny H Wong, Justin C. Y Wu, Joseph J. Y Sung, Siew C Ng
    Journal of Crohn's and Colitis.2017; 11(9): 1071.     CrossRef
  • Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
    Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
    The American Journal of the Medical Sciences.2017; 353(5): 439.     CrossRef
  • Fecal calprotectin as a non‐invasive biomarker for intestinal involvement of Behçet's disease
    Duk Hwan Kim, Yehyun Park, Bun Kim, Seung Won Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Journal of Gastroenterology and Hepatology.2017; 32(3): 595.     CrossRef
  • Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease
    Christopher Ma, Rowan Lumb, Emily V. Walker, Rae R. Foshaug, ThucNhi T. Dang, Sanam Verma, Vivian W. Huang, Karen I. Kroeker, Karen Wong, Levinus A. Dieleman, Richard N. Fedorak, Brendan P. Halloran
    Inflammatory Bowel Diseases.2017; 23(9): 1643.     CrossRef
  • Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization
    Shuhei Fukunaga, Kotaro Kuwaki, Keiichi Mitsuyama, Hidetoshi Takedatsu, Shinichiro Yoshioka, Hiroshi Yamasaki, Ryosuke Yamauchi, Atsushi Mori, Tatsuyuki Kakuma, Osamu Tsuruta, Takuji Torimura
    International Journal of Molecular Medicine.2017;[Epub]     CrossRef
  • Fecal biomarkers in inflammatory bowel disease: how, when and why?
    Paula Ministro, Diana Martins
    Expert Review of Gastroenterology & Hepatology.2017; 11(4): 317.     CrossRef
  • Assessment of disease activity by fecal immunochemical test in ulcerative colitis
    Dae Gon Ryu, Hyung Wook Kim, Su Bum Park, Dae Hwan Kang, Cheol Woong Choi, Su Jin Kim, Hyeong Seok Nam
    World Journal of Gastroenterology.2016; 22(48): 10617.     CrossRef
  • Does Gastric Surgery (Such as Bariatric Surgery) Impact the Risk of Intestinal Inflammation?
    Daniel Gero, Christian A. Gutschow, Marco Bueter
    Inflammatory Intestinal Diseases.2016; 1(3): 129.     CrossRef
  • 7,178 View
  • 104 Download
  • 47 Web of Science
  • 45 Crossref
Close layer
Current status of biosimilars in the treatment of inflammatory bowel diseases
Dong Il Park
Intest Res 2016;14(1):15-20.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.15
AbstractAbstract PDFPubReaderePub

Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden on National Healthcare Systems. The development of first biosimilar to infliximab, CT-P13 (Remsima; Celltrion Inc., Incheon, Korea and Inflextra; Hospiral, Lake Forest, Illinois, USA) has become another way to decrease the medical care cost and increase patient treatment option, but, actual equivalence of efficacy and safety of CT-P13 was investigated in rheumatic diseases only. The extrapolation of outcome from rheumatic trials to IBD and the interchangeability of CT-P13 with infliximab have come to be a matter of concern. Two recent retrospective studies reported the similarity of CT-P13 in terms of efficacy and safety. Infliximab biosimilars may be promising new treatment options for IBD patients, however, well-designed, prospective randomized non-inferiority trials should be needed to confidently integrate infliximab biosimilars into IBD treatment.

Citations

Citations to this article as recorded by  
  • Drugs with the highest drug expenditure in the Republic of Serbia
    Boris Milijašević, Anđela Milak, Milan Ubavić, Dane Krtinić, Gorana Nedin-Ranković, Hristina Jovanović, Hristina Trajković, Dragana Milijašević, Radmila Popović, Nemanja Todorović, Mladena Lalić-Popović, Nikola Vukosav, Branko Baljak, Milan Tošić, Radmila
    Hospital Pharmacology - International Multidisciplinary Journal.2023; 10(2): 1301.     CrossRef
  • International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States
    Yun‐Kyoung Song, Nayoung Han, Gilbert J. Burckart, Jung Mi Oh
    Clinical Pharmacology & Therapeutics.2020; 107(3): 530.     CrossRef
  • Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
    Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar, Edward V. Loftus
    Intestinal Research.2020; 18(1): 34.     CrossRef
  • Characteristics of biological therapy in pediatric patients with Crohn’s disease
    Andras Tarnok, Zoltan Kiss, Orsolya Kadenczki, Gabor Veres
    Expert Opinion on Biological Therapy.2019; 19(3): 181.     CrossRef
  • Use of Biosimilars in Pediatric Inflammatory Bowel Disease
    Lissy de Ridder, Amit Assa, Jiri Bronsky, Claudio Romano, Richard K. Russell, Nadeem A. Afzal, Almuthe C. Hauer, Daniela Knafelz, Paolo Lionetti, Caterina Strisciuglio, Gábor Veres, Harland Winter, Victorien M. Wolters, Malgorzata Sladek, Arnold G. Vulto,
    Journal of Pediatric Gastroenterology and Nutrition.2019; 68(1): 144.     CrossRef
  • Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review
    Laura Martelli, Laurent Peyrin-Biroulet
    Current Medicinal Chemistry.2019; 26(2): 270.     CrossRef
  • Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
    Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi
    Intestinal Research.2019; 17(4): 504.     CrossRef
  • Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians
    Soo-Kyung Park, Won Moon, Eun Soo Kim, Sang Hyun Park, Dong Il Park
    The Korean Journal of Gastroenterology.2019; 74(6): 333.     CrossRef
  • The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
    G.S. Fernandes, C. Sternberg, G. Lopes, R. Chammas, M.A.C. Gifoni, R.A. Gil, D.V. Araujo
    Brazilian Journal of Medical and Biological Research.2018;[Epub]     CrossRef
  • Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
    Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood
    Intestinal Research.2018; 16(1): 83.     CrossRef
  • Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence
    Sean McConachie, Sheila M. Wilhelm, Pramodini B. Kale-Pradhan
    Expert Review of Clinical Pharmacology.2017; 10(4): 391.     CrossRef
  • Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
    András Inotai, Christiaan P.J Prins, Marcell Csanádi, Dinko Vitezic, Catalin Codreanu, Zoltán Kaló
    Expert Opinion on Biological Therapy.2017; 17(8): 915.     CrossRef
  • Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model
    Seung Kak Shin, Jae Hee Cho, Eui Joo Kim, Eun-Kyung Kim, Dong Kyun Park, Kwang An Kwon, Jun-Won Chung, Kyoung Oh Kim, Yoon Jae Kim
    World Journal of Gastroenterology.2017; 23(25): 4559.     CrossRef
  • Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease
    Sang Hyoung Park, Satimai Aniwan, Edward V Loftus
    Current Opinion in Pharmacology.2017; 37: 65.     CrossRef
  • Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
    Seong Ran Jeon
    Gut and Liver.2017; 11(2): 171.     CrossRef
  • 5,393 View
  • 49 Download
  • 15 Web of Science
  • 15 Crossref
Close layer
Current status and future perspectives of capsule endoscopy
Hyun Joo Song, Ki-Nam Shim
Intest Res 2016;14(1):21-29.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.21
AbstractAbstract PDFPubReaderePub

Small bowel capsule endoscopy (CE) was first introduced 15 years ago, and a large amount of literature has since been produced, focused on its indication, diagnostic yields, and safety. Guidelines that have made CE the primary diagnostic tool for small bowel disease have been created. Since its initial use in the small bowel, CE has been used for the esophagus, stomach, and colon. The primary indications for small bowel CE are obscure gastrointestinal bleeding, unexplained iron deficiency anemia, suspected Crohn's disease, small bowel tumors, nonsteroidal anti-inflammatory drug enteropathy, portal hypertensive enteropathy, celiac disease, etc. Colon CE provides an alternative to conventional colonoscopy, with possible use in colorectal cancer screening. Guidelines for optimal bowel preparation of CE have been suggested. The main challenges in CE are the development of new devices with the ability to provide therapy, air inflation for better visualization of the small bowel, biopsy sampling systems attached to the capsule, and the possibility of guiding and moving the capsule by an external motion controller. We review the current status and future directions of CE, and address all aspects of clinical practice, including the role of CE and long-term clinical outcomes.

Citations

Citations to this article as recorded by  
  • Advances in implantable capsule robots for monitoring and treatment of gastrointestinal diseases
    Xiaofeng Wang, Hao Xu, Yanlong Ren, Ying Yuan, Fei Deng, Wei Gao, Zheng Lou, Xian-Tao Song, Hao Guo, Wei Han, Lili Wang
    Materials Science and Engineering: R: Reports.2025; 163: 100943.     CrossRef
  • Neutrophils in the Focus: Impact on Neuroimmune Dynamics and the Gut–Brain Axis
    Antea Krsek, Lara Baticic
    Gastrointestinal Disorders.2024; 6(3): 557.     CrossRef
  • Capsule endoscopy for small bowel bleed: Current update
    Uday C. Ghoshal, Akash Roy, Mahesh K. Goenka
    Indian Journal of Gastroenterology.2024; 43(5): 896.     CrossRef
  • New endoscopic capsule vs upper gastrointestinal endoscopy in preoperative work-up of obese candidate for bariatric surgery: Relevance of a pilot study in the COVID-19 era
    Giuseppe Galloro, Mario Musella, Saverio Siciliano, Giovanna Berardi, Antonio Vitiello, Nunzio Velotti, Fernando Rizzello, Paolo Gionchetti, Carlo Calabrese
    Endoscopy International Open.2022; 10(02): E183.     CrossRef
  • Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
    Nick Lung-Ngai Ting, Harry Cheuk-Hay Lau, Jun Yu
    Gut.2022; 71(7): 1412.     CrossRef
  • Iron Deficiency Anaemia and Anaemia of Inflammation in Enteropathies Caused by Commonest Small Intestine Disorders: Current Evidence
    Olesja Basina, Jelena Derova, Aleksejs Derovs, Sandra Lejniece
    Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences..2022; 76(5-6): 561.     CrossRef
  • Double-headed small-bowel capsule endoscopy: Real-world experience from a multi-centre British study
    DE Yung, AR Robertson, M Davie, R Sidhu, M McAlindon, I Rahman, P Patel, L Sinha, S Mason, J Brzeszczynska, S Douglas, JN Plevris, A Koulaouzidis
    Digestive and Liver Disease.2021; 53(4): 461.     CrossRef
  • Clinical Outcomes between P1 and P0 Lesions for Obscure Gastrointestinal Bleeding with Negative Computed Tomography and Capsule Endoscopy
    Young Kyu Cho, Heesu Park, Jung Rock Moon, Seong Ran Jeon, Hyun Gun Kim, Tae Hee Lee, Junseok Park, Jin-Oh Kim, Joon Seong Lee, Hyeon Jeong Goong, Bong Min Ko, Suyeon Park
    Diagnostics.2021; 11(4): 657.     CrossRef
  • Application of Structural Entropy and Spatial Filling Factor in Colonoscopy Image Classification
    Brigita Sziová, Szilvia Nagy, Zoltán Fazekas
    Entropy.2021; 23(8): 936.     CrossRef
  • Indicaciones, rendimiento diagnóstico y seguridad de la cápsula endoscópica de intestino delgado en pacientes mexicanos. Experiencia de un centro de tercer nivel
    G. Blanco-Velasco, C. Mendoza-Segura, O.M. Solórzano-Pineda, O.V. Hernández-Mondragón, V. Paz-Flores, J.M. Blancas-Valencia
    Revista de Gastroenterología de México.2020; 85(2): 140.     CrossRef
  • Indications for small bowel capsule endoscopy and its safety and diagnostic yield in Mexican patients. Experience at a tertiary care hospital center
    G. Blanco-Velasco, C. Mendoza-Segura, O.M. Solórzano-Pineda, O.V. Hernández-Mondragón, V. Paz-Flores, J.M. Blancas-Valencia
    Revista de Gastroenterología de México (English Edition).2020; 85(2): 140.     CrossRef
  • Analysis of current and future technologies of capsule endoscopy: A mini review
    Brown Alexander P, Jayatissa Ahalapitiya H
    Archives of Preventive Medicine.2020; : 031.     CrossRef
  • Capsule endoscopy for small‐intestinal disorders: Current status
    Naoki Hosoe, Kaoru Takabayashi, Haruhiko Ogata, Takanori Kanai
    Digestive Endoscopy.2019; 31(5): 498.     CrossRef
  • Evaluation of Gastric Disease with Capsule Endoscopy
    Seung-Joo Nam, Hyun Seok Lee, Yun Jeong Lim
    Clinical Endoscopy.2018; 51(4): 323.     CrossRef
  • Rebleeding rate and risk factors in nonsteroidal anti‐inflammatory drug‐induced enteropathy
    Junseok Park, Seong Ran Jeon, Jin‐Oh Kim, Hyun Gun Kim, Tae Hee Lee, Jun‐Hyung Cho, Bong Min Ko, Joon Seong Lee, Moon Sung Lee
    Journal of Digestive Diseases.2018; 19(5): 279.     CrossRef
  • The gut microbiota influences anticancer immunosurveillance and general health
    Bertrand Routy, Vancheswaran Gopalakrishnan, Romain Daillère, Laurence Zitvogel, Jennifer A. Wargo, Guido Kroemer
    Nature Reviews Clinical Oncology.2018; 15(6): 382.     CrossRef
  • Diagnostic Value of Small Bowel Capsule Endoscopy in Isolated Ileitis: A CAPENTRY Study
    Hyun Seok Lee, Yun Jeong Lim, Ki Nam Shim, Chang Mo Moon, Hyun Joo Song, Jin Oh Kim, Seong Ran Jeon, Dae Young Jung, Ji Hyun Kim, Kyeong Ok Kim, Bo-In Lee
    Digestive Diseases and Sciences.2017; 62(1): 180.     CrossRef
  • Quality Indicators for Small Bowel Capsule Endoscopy
    Ki-Nam Shim, Seong Ran Jeon, Hyun Joo Jang, Jinsu Kim, Yun Jeong Lim, Kyeong Ok Kim, Hyun Joo Song, Hyun Seok Lee, Jae Jun Park, Ji Hyun Kim, Jaeyoung Chun, Soo Jung Park, Dong-Hoon Yang, Yang Won Min, Bora Keum, Bo-In Lee
    Clinical Endoscopy.2017; 50(2): 148.     CrossRef
  • Role of capsule endoscopy in suspected or established Crohn's disease in real practice
    Hyun Joo Jang
    Intestinal Research.2017; 15(4): 431.     CrossRef
  • Intraepithelial lymphocytes, scores, mimickers and challenges in diagnosing gluten-sensitive enteropathy (celiac disease)
    Consolato Sergi, Fan Shen, Gerd Bouma
    World Journal of Gastroenterology.2017; 23(4): 573.     CrossRef
  • Results of the first survey for the current status of inflammatory bowel disease management in Asian countries
    Ji Won Kim
    Intestinal Research.2016; 14(3): 199.     CrossRef
  • 7,235 View
  • 88 Download
  • 21 Web of Science
  • 21 Crossref
Close layer
Original Articles
Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam
Eun Ji Lee, Tae Oh Kim, Geun Am Song, Jong hun Lee, Hyung Wook Kim, Sam Ryong Jee, Seun Ja Park, Hyun Jin Kim, Jong Ha Park
Intest Res 2016;14(1):30-36.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.30
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Crohn's disease (CD) is a chronic inflammatory bowel disease that presents with variable features and repeated disease aggravation. The incidence of CD is increasing in Korea. We evaluated the clinical features of CD in a study population in Busan and Gyeongnam, Korea.

Methods

A hospital-based analysis included 619 patients diagnosed with CD between March 1986 and February 2013 from seven tertiary care hospitals in Busan and Gyeongnam. Individual case records were reviewed with regard to age at diagnosis, sex, disease location, disease behavior, and medical and surgical treatments received during the follow-up period.

Results

The cumulative frequency of patients diagnosed with CD revealed a continued increase in the number of cases reported yearly. The male-to-female ratio was 2.5:1 and the median age at diagnosis was 24 years. At diagnosis, 114 (18.4%) had isolated small bowel disease, 144 (23.3%) had isolated colonic disease, and 358 patients (57.8%) presented with disease in the small bowel and colon. The number of patients presenting with stricturing or penetrating disease behavior was 291 (47%) at the final evaluation. In total, 111 (17.9%) patients underwent intestinal resections.

Conclusions

A continued increase in the number of patients diagnosed with CD was found in Busan and Gyeongnam as observed in other regions. We report results similar to that of other Korean studies in terms of sex distribution, age, and location of disease.

Citations

Citations to this article as recorded by  
  • Association between inflammatory bowel disease and osteoporosis in European and East Asian populations: exploring causality, mediation by nutritional status, and shared genetic architecture
    Jian Kang, Xize Wu, Yue Li, Shuangli Zhao, Shixuan Wang, Dongdong Yu
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • NF-kappa B activation correlates with disease phenotype in Crohn’s disease
    Yoo Min Han, Jaemoon Koh, Ji Won Kim, Changhyun Lee, Seong-Joon Koh, ByeongGwan Kim, Kook Lae Lee, Jong Pil Im, Joo Sung Kim, Gernot Sellge
    PLOS ONE.2017; 12(7): e0182071.     CrossRef
  • Are there interregional differences in the epidemiology and clinical characteristics of Crohn's disease in the Asia-Pacific region?
    Sinwon Lee, Byong Duk Ye
    Intestinal Research.2016; 14(1): 2.     CrossRef
  • Changing epidemiological trends of inflammatory bowel disease in Asia
    Wee Khoon Ng, Sunny H. Wong, Siew C. Ng
    Intestinal Research.2016; 14(2): 111.     CrossRef
  • 5,123 View
  • 47 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
The predictive variable regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal healing
Takuya Yoshino, Kohei Yamakawa, Satoshi Nishimura, Koutaro Watanabe, Shujiro Yazumi
Intest Res 2016;14(1):37-42.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.37
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Mucosal healing (MH) is a proposed therapeutic goal for patients with ulcerative colitis (UC). Whether MH is the final goal for UC, however, remains under debate. Therefore, to elucidate clinical variables predicting relapse after MH in UC could be useful for establishing further therapeutic strategy. The aim of this study is to evaluate the predictive variables for relapse in UC-patients after achieving MH.

Methods

From April 2010 to February 2015, 298 UC-patients treated at Kitano Hospital were retrospectively analyzed. MH was defined as Mayo endoscopic subscore of 0 or 1. The cumulative relapse free rate after achieving MH was evaluated. Predictive variables for relapse in UC-patients were assessed by Cox regression analysis.

Results

Of 298 UC-patients, 88 (29.5%) achieved MH. Of the 88 UC patients who achieved MH, 21 (23.9%) experienced UC-relapse. Based on Kaplan-Meier analysis, the cumulative relapse free rate at 1, 3, and 5 years after achieving MH was 87.9%, 70.2%, and 63.8%, respectively. The cumulative relapse free rate tended to be higher in the Mayo-0 group (76.9%) than in the Mayo-1 group (54.1%) at 5 years, although the difference was not statistically significant (P=0.313). Cox regression analysis indicated that the use of an immunomodulator was a predictive variable for relapse in UC-patients after achieving MH (P=0.035).

Conclusions

Our data demonstrated that the prognosis of UC patients after achieving endoscopic MH could be based on UC refractoriness requiring an immunomodulator.

Citations

Citations to this article as recorded by  
  • Deep mucosal healing in ulcerative colitis: how deep is better?
    Xin Jin, Yan You, Gechong Ruan, Weixun Zhou, Ji Li, Jingnan Li
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis
    Angelo Viscido, Marco Valvano, Gianpiero Stefanelli, Annalisa Capannolo, Chiara Castellini, Eugenia Onori, Antonio Ciccone, Filippo Vernia, Giovanni Latella
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
    Natsuki Ishida, Tomoharu Matsuura, Yusuke Asai, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
    Clinical and Translational Gastroenterology.2022; 13(7): e00501.     CrossRef
  • Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse
    Natsuki Ishida, Shunya Onoue, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
    International Journal of Colorectal Disease.2021; 36(12): 2661.     CrossRef
  • Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
    Toshifumi Hibi, Makoto Naganuma, Eisei Oda, Yoji Yamada, Yoshitomo Chujoh, Ryoichi Yoshihara, Mamoru Watanabe
    Intestinal Research.2020; 18(1): 56.     CrossRef
  • Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis
    Hyuk Yoon, Sushrut Jangi, Parambir S. Dulai, Brigid S. Boland, Larry J. Prokop, Vipul Jairath, Brian G. Feagan, William J. Sandborn, Siddharth Singh
    Gastroenterology.2020; 159(4): 1262.     CrossRef
  • Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
    Makoto Naganuma, Fumihito Hirai, Kiyonori Kobayashi, Kenji Watanabe, Ken Takeuchi, Nobuo Aoyama, Hiroshi Nozawa, Satoshi Motoya, Toshihide Ohmori, Akio Harada, Yushi Nagai, Takayuki Abe, Yoji Yamada, Katsutoshi Inagaki, Naoki Shimizu, Takanori Kanai, Mamo
    PLOS ONE.2019; 14(8): e0220413.     CrossRef
  • Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing
    Takayuki Yamamoto, Takahiro Shimoyama, Satoru Umegae, Koichi Matsumoto
    Clinical and Translational Gastroenterology.2018; 9(3): e136.     CrossRef
  • European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease
    Glen Doherty, Konstantinos H Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska, Edouard Louis
    Journal of Crohn's and Colitis.2018; 12(1): 17.     CrossRef
  • Evaluation of the Potential Antioxidant Role of High-Density Lipoprotein-Cholesterol (HDL-C) in Patients with Ulcerative Colitis
    Mostafa Vaghari Tabari, Soheila Moein, Durdi Qujeq, Mehrdad Kashifard, Javaad Shokri Shirvani, Karimollah Hajian Tilaki, Gholamreza Farshidfar
    Annals of Colorectal Research.2017;[Epub]     CrossRef
  • 5,265 View
  • 48 Download
  • 9 Web of Science
  • 10 Crossref
Close layer
The prevalence and clinical characteristics of anemia in Korean patients with inflammatory bowel disease
Dae Sung Lee, Ki Bae Bang, Ji Yeon Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Young Choi, Dong Il Park
Intest Res 2016;14(1):43-49.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.43
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Quality of life is closely related to anemia in patients with inflammatory bowel disease (IBD). Several studies have reported on anemia in patients with IBD in Western countries. This study investigated the prevalence and clinical characteristics of anemia in Korean patients with IBD.

Methods

We reviewed the medical records of 92 patients with ulcerative colitis (UC) and 76 patients with Crohn's disease (CD) who were followed regularly at a single tertiary medical center in Korea between January 2003 and December 2012. Hemoglobin (Hb) thresholds used to define anemia were <13.0 g/dL in men and <12.0 g/dL in women according to the World Health Organization criteria. We chose the lowest Hb level in each year as a representative value because Hb levels changed at each examination and anemia was associated with disease deterioration. The relationship between clinical variables and lowest Hb level was assessed.

Results

The prevalence of anemia was 36.3% in patients with UC and 41.6% in patients with CD. Anemia in patients with CD was associated with hospital admission, 5-aminosalicylate (5-ASA) and infliximab treatment in men. Anemia in patients with UC was associated with hospital admission, oral steroid use, thiopurine and infliximab treatment in men.

Conclusions

The prevalence of anemia in Korean patients with IBD was comparable to that of patients in Western countries. Anemia was associated with male patients with CD who were admitted to the hospital and received medications including 5-ASA and infliximab, and men with UC who were admitted to the hospital and received medications including oral steroids, thiopurine and infliximab.

Citations

Citations to this article as recorded by  
  • Clinical characteristics and north-south differences of inflammatory bowel disease in China: A cross-sectional study and meta-analysis
    Qi Liang, Bo Qu, Chunye Li, Yue Hu, Chunyi Yang, Tingting Yang, Yuzhu Di, Hui Li
    Frigid Zone Medicine.2024; 4(1): 23.     CrossRef
  • Clinical and Laboratory Characteristics of Anaemia in Hospitalized Patients with Inflammatory Bowel Disease
    Małgorzata Woźniak, Anna Borkowska, Marta Jastrzębska, Marcin Sochal, Ewa Małecka-Wojciesko, Renata Talar-Wojnarowska
    Journal of Clinical Medicine.2023; 12(7): 2447.     CrossRef
  • Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study
    Natália Souza Nunes Siqueira, Livia Bitencourt Pascoal, Bruno Lima Rodrigues, Marina Moreira de Castro, Alan Sidnei Corrêa Martins, Dante Orsetti Silva Araújo, Luis Eduardo Miani Gomes, Michel Gardere Camargo, Maria de Lourdes Setsuko Ayrizono, Raquel Fra
    World Journal of Clinical Cases.2023; 11(12): 2740.     CrossRef
  • ANEMIA AND IRON DEFICIENCY IN INFLAMMATORY BOWEL DISEASE PATIENTS IN A REFERRAL CENTER IN BRAZIL: PREVALENCE AND RISK FACTORS
    Rogério Serafim PARRA, Marley Ribeiro FEITOSA, Sandro da Costa FERREIRA, José Joaquim Ribeiro da ROCHA, Luiz Ernesto de Almeida TRONCON, Omar FÉRES
    Arquivos de Gastroenterologia.2020; 57(3): 272.     CrossRef
  • Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease
    Göksel Bengi, Hatice Keyvan, Seda Bayrak Durmaz, Hale Akpınar
    World Journal of Gastroenterology.2018; 24(36): 4186.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Should asymptomatic young men with iron deficiency anemia necessarily undergo endoscopy?
    Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
    The Korean Journal of Internal Medicine.2018; 33(6): 1084.     CrossRef
  • Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients
    Alfredo J. Lucendo, Ángel Arias, Óscar Roncero, Daniel Hervías, Cristina Verdejo, Carmen Naveas-Polo, Abdelmouneim Bouhmidi, Rufo Lorente, Luis Miguel Alcázar, Irina Salueña, Julio A. García-Quiñones, María Jesús Carrillo-Ramos
    Digestive and Liver Disease.2017; 49(4): 405.     CrossRef
  • 5,519 View
  • 65 Download
  • 8 Web of Science
  • 8 Crossref
Close layer
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
Yasuo Suzuki, Mitsuo Iida, Hiroaki Ito, Isamu Saida, Toshifumi Hibi
Intest Res 2016;14(1):50-59.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.50
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

The therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients. This study aimed to provide new insight for dose optimization using two doses of pH-dependent release mesalamine for induction of remission of moderately active ulcerative colitis (UC).

Methods

In a multicenter, double-blind, randomized study, 110 patients with moderately active UC were assigned to two groups after treatment with a constant dose of mesalamine. Fifty-five patients were treated with a pH-dependent release formulation of 3.6 or 4.8 g/day for 8 weeks. The primary endpoint was a decrease in the UC disease activity index (UCDAI) adjusted by covariates.

Results

In the full analysis set (n=110), the mean decrease in UCDAI was 3.1 in the 3.6 g/day group and 3.4 in the 4.8 g/day group (P>0.05). In a subgroup analysis, the effectiveness of the 4.8 g/day dose was greater in particular populations, such as those who had been previously treated with a lower dose of mesalamine and those with more severe disease. The safety was comparable between the two groups.

Conclusions

The results suggest that treatment with pH-dependent release mesalamine at either 3.6 or 4.8 g/day was effective and safe for the induction of remission in patients with moderately active UC. However, the patients receiving mesalamine at 2.4 g/day but in whom the therapeutic effect is not sufficient and having more severe symptoms (UCDAI 9-10), benefit from higher doses of mesalamine compared to others.

Citations

Citations to this article as recorded by  
  • Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
    Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kir
    Intestinal Research.2020; 18(4): 355.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
    Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi
    Intestinal Research.2017; 15(3): 368.     CrossRef
  • Remission endpoints in ulcerative colitis: A systematic review
    Maki Jitsumura, Rory Frederick Kokelaar, Dean Anthony Harris
    World Journal of Meta-Analysis.2017; 5(4): 85.     CrossRef
  • Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease
    Celestine Wong, Philip Harris, Lynnette Ferguson
    International Journal of Molecular Sciences.2016; 17(6): 919.     CrossRef
  • What is the real-life maintenance mesalazine dose in ulcerative colitis?
    Alicia Algaba, Iván Guerra, Ana García García de Paredes, María Hernández Tejero, Carlos Ferre, Daniel Bonillo, Lara Aguilera, Antonio López-Sanromán, Fernando Bermejo
    Revista Española de Enfermedades Digestivas.2016;[Epub]     CrossRef
  • 5,562 View
  • 66 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Gastric lesions in patients with Crohn's disease in Korea: a multicenter study
Hoonsub So, Byong Duk Ye, Young Soo Park, Jihun Kim, Joo Sung Kim, Won Moon, Kang-Moon Lee, You Sun Kim, Bora Keum, Seong-Eun Kim, Kyeong Ok Kim, Eun Soo Kim, Chang Kyun Lee, Sung Pil Hong, Jong Pil Im, Ja Seol Koo, Chang Hwan Choi, Jeong Eun Shin, Bo In Lee, Kyu Chan Huh, Young-Ho Kim, Hyun-Soo Kim, Young Sook Park, Dong Soo Han
Intest Res 2016;14(1):60-68.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.60
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Gastric pathology and Helicobacter pylori (H. pylori) infection among Asian patients with Crohn's disease (CD) are still unclear. We evaluated gastric histologic features and frequency of H. pylori infection in Korean patients with CD.

Methods

Among 492 patients with CD receiving upper gastrointestinal (GI) endoscopic evaluation in 19 Korean hospitals, we evaluated the endoscopic findings and gastric histopathologic features of 47 patients for our study. Histopathologic classification was performed using gastric biopsy tissues, and H. pylori infection was determined using the rapid urease test and histology.

Results

There were 36 men (76.6%), and the median age of patients at the time of upper GI endoscopy was 23.8 years (range, 14.2–60.5). For CD phenotype, ileocolonic disease was observed in 38 patients (80.9%), and non-stricturing, non-penetrating disease in 31 patients (66.0%). Twenty-eight patients (59.6%) complained of upper GI symptoms. Erosive gastritis was the most common gross gastric feature (66.0%). Histopathologically, H. pylori-negative chronic active gastritis (38.3%) was the most frequent finding. H. pylori testing was positive in 11 patients (23.4%), and gastric noncaseating granulomata were detected in 4 patients (8.5%). Gastric noncaseating granuloma showed a statistically significant association with perianal abscess/fistula (P=0.0496).

Conclusions

H. pylori-negative chronic active gastritis appears to be frequent among Korean patients with CD. The frequency of H. pylori infection was comparable with previous studies. An association with perianal complications suggests a prognostic value for gastric noncaseating granuloma in patients with CD.

Citations

Citations to this article as recorded by  
  • Endoscopic findings in the upper gastrointestinal tract in patients with Crohn’s disease are common, highly specific, and associated with chronic gastritis
    Katarzyna Graca-Pakulska, Wojciech Błogowski, Iwona Zawada, Anna Deskur, Krzysztof Dąbkowski, Elżbieta Urasińska, Teresa Starzyńska
    Scientific Reports.2023;[Epub]     CrossRef
  • Detection Rates of Non-Cavitary Epithelioid Cell Granuloma by Gastrointestinal Biopsy in Patients with Treatment-Naïve Crohn’s Disease
    Katsuya Endo, Yoko Kawakami, Yuki Yoshino, Shiho Kondo, Daisuke Fukushi, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Kazuhiro Murakami, Kennichi Satoh
    Inflammatory Intestinal Diseases.2023; 8(3): 105.     CrossRef
  • Beyond Helicobacter: dealing with other variants of gastritis—an algorithmic approach
    Hala El‐Zimaity, Robert H Riddell
    Histopathology.2021; 78(1): 48.     CrossRef
  • Endoscopic and Histopathological Findings of the Esophagus, Stomach, and Duodenum in Patients with Crohn’s Disease from a Reference Center in Bahia, Brazil
    Andrea Maia Pimentel, Luiz Antônio Rodrigues de Freitas, Rita de Cássia Reis Cruz, Isaac Neri de Novais Silva, Laíla Damasceno Andrade, Paola Nascimento Marques, Júlia Cordeiro Braga, Flora Maria Lorenzo Fortes, Katia Rejane Marques Brito, Jaciane Araújo
    Clinics and Practice.2021; 11(2): 374.     CrossRef
  • The gastric microbiota in patients with Crohn’s disease; a preliminary study
    Jerzy Ostrowski, Maria Kulecka, Iwona Zawada, Natalia Żeber-Lubecka, Agnieszka Paziewska, Katarzyna Graca-Pakulska, Krzysztof Dąbkowski, Karolina Skubisz, Patrycja Cybula, Filip Ambrożkiewicz, Elżbieta Urasińska, Michał Mikula, Teresa Starzyńska
    Scientific Reports.2021;[Epub]     CrossRef
  • Associations between the Presence of Granulomata and Disease Phenotype and Outcomes in Children Diagnosed with Crohn’s Disease
    Laura Appleton, Euan Watt, Fiona Jagger, Richard Hansen, Richard B. Gearry, Andrew S. Day
    Gastrointestinal Disorders.2020; 2(2): 164.     CrossRef
  • Ovarian Crohn’s Disease: A Case Report and Review of the Literature
    Hamza Mohammed, Rana Bokhary, Mohammed Nassif, Mahmoud Mosli, Haruhiko Sugimura
    Case Reports in Gastrointestinal Medicine.2020; 2020: 1.     CrossRef
  • Crohn’s disease of esophagus, stomach and duodenum
    Andréa Maia Pimentel, Raquel Rocha, Genoile Oliveira Santana
    World Journal of Gastrointestinal Pharmacology and Therapeutics.2019; 10(2): 35.     CrossRef
  • Prognostic significance of granulomas in children with Crohn’s disease
    Benjamin Rothschild, Firas Rinawi, Yonatan Herman, Osnat Nir, Raanan Shamir, Amit Assa
    Scandinavian Journal of Gastroenterology.2017; 52(6-7): 716.     CrossRef
  • Endoscopic Bamboo Joint-like Appearance of the Stomach in Crohn's Disease
    Kwang Il Seo, Won Moon
    The Korean Journal of Gastroenterology.2017; 69(2): 151.     CrossRef
  • Characteristics of Upper Gastrointestinal Tract Involvement in Korean Pediatric Crohn's Disease: A Multicenter Study
    Ji Hyoung Park, Hye Na Nam, Ji-Hyuk Lee, Jeana Hong, Dae Yong Yi, Eell Ryoo, In Sang Jeon, Hann Tchah
    Pediatric Gastroenterology, Hepatology & Nutrition.2017; 20(4): 227.     CrossRef
  • Increased duodenal expression of miR-146a and -155 in pediatric Crohn’s disease
    Dániel Szűcs, Nóra Judit Béres, Réka Rokonay, Kriszta Boros, Katalin Borka, Zoltán Kiss, András Arató, Attila J Szabó, Ádám Vannay, Erna Sziksz, Csaba Bereczki, Gábor Veres
    World Journal of Gastroenterology.2016; 22(26): 6027.     CrossRef
  • 7,233 View
  • 70 Download
  • 10 Web of Science
  • 12 Crossref
Close layer
The role of capsule endoscopy in etiological diagnosis and management of obscure gastrointestinal bleeding
Vikas Pandey, Meghraj Ingle, Nilesh Pandav, Pathik Parikh, Jignesh Patel, Aniruddha Phadke, Prabha Sawant
Intest Res 2016;14(1):69-74.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.69
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

To investigate the various etiologies, yields, and effects of capsule endoscopy (CE) on management and complications, along with follow up of patients with obscure gastrointestinal (GI) bleeding.

Methods

The study group of patients included those having obscure, overt, or occult GI bleeding. The findings were categorized as (A) obvious/definitive, (B) equivocal, or (C) negative. Any significant alteration in patient management post CE in the form of drug or surgical intervention was noted.

Results

Total patients included in the study were 68 (48 males and 20 females). The ratio of male:female was 2.4:1. The age ranged between 16 years to 77 years. Mean age for males was 62±14 years, for females 58±16 years. The total yield of CE with definitive lesions was in 44/68 (65.0%) of patients. In descending order (A) angiodysplasia 16/68 (23.53%), (B) Crohn's disease 10/68 (14.70%), (C) non-steroidal anti-inflammatory drug enteropathy 8/68 (11.76%), (D) small bowel ulcers 4/68 (5.88%), (E) jejunal and ileal polyps 2/68 (2.94%), (F) intestinal lymphangiectasis 2/68 (2.94%), and (G) ileal hemangiomas 2/68 (2.94%) were followed. Equivocal findings 12/68 (17.65%) and negative study 12/68 (17.65%) was found. Complications in the form of capsule retention in the distal ileum were noted in 2/68 (2.94%) subjects. Statistically, there was a higher probability of finding the etiology if the CE was done during an episode of bleeding.

Conclusions

CE plays an important role in diagnosing etiologies of obscure GI bleeding. Its role in influencing the management outcome is vital.

Citations

Citations to this article as recorded by  
  • Capsule endoscopy for obscure gastrointestinal bleed in the tropics: A single-center experience on 350 patients
    Uday C. Ghoshal, Piyush Mishra, Akash Mathur, Sai Prathap Reddy, Bushra Fatima, Asha Misra
    Indian Journal of Gastroenterology.2024; 43(5): 1045.     CrossRef
  • Capsule endoscopy for small bowel bleed: Current update
    Uday C. Ghoshal, Akash Roy, Mahesh K. Goenka
    Indian Journal of Gastroenterology.2024; 43(5): 896.     CrossRef
  • An intelligent intestinal bleeding diagnosis and treatment capsule system based on color recognition
    Panpan Qiao, Luo Yu, Hongying Liu, Xueping Yan, Xitian Pi
    Biomedical Microdevices.2023;[Epub]     CrossRef
  • Systematic review and meta‐analysis of the diagnostic and therapeutic yield of small bowel endoscopy in patients with overt small bowel bleeding
    Genta Uchida, Masanao Nakamura, Takeshi Yamamura, Kazuhiro Furukawa, Hiroki Kawashima, Takashi Honda, Masatoshi Ishigami, Mitsuhiro Fujishiro
    Digestive Endoscopy.2021; 33(1): 66.     CrossRef
  • Comparison in the Diagnostic Yield between “Pillcam SB3” Capsule Endoscopy and “OMOM Smart Capsule 2” in Small Bowel Bleeding: A Randomized Head-to-Head Study
    Gerardo Blanco-Velasco, Raúl Antonio Zamarripa-Mottú, Omar Michel Solórzano-Pineda, Miguel Mascarenhas-Saraiva, Juan Manuel Blancas-Valencia, Oscar Victor Hernández-Mondragón
    Digestive Diseases.2021; 39(3): 211.     CrossRef
  • Heterotopia de mucosa gástrica en intestino delgado, hallazgo en videocápsula endoscópica. Reporte de caso
    Santiago Castaño, Natalia Calvache, Mauricio Sepúlveda
    Revista Colombiana de Gastroenterología.2019; 34(3): 314.     CrossRef
  • Meta-analysis shows similar re-bleeding rates among Western and Eastern populations after index video capsule endoscopy
    Georgios Tziatzios, Paraskevas Gkolfakis, Cesare Hassan, Ervin Toth, Angelo Zullo, Anastasios Koulaouzidis, George D. Dimitriadis, Konstantinos Triantafyllou
    Digestive and Liver Disease.2018; 50(3): 226.     CrossRef
  • Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre
    S. Chetcuti Zammit, D. S. Sanders, R. Sidhu
    Scandinavian Journal of Gastroenterology.2017; : 1.     CrossRef
  • Role of capsule endoscopy in suspected or established Crohn's disease in real practice
    Hyun Joo Jang
    Intestinal Research.2017; 15(4): 431.     CrossRef
  • The Role of Dynamic Contrast-enhanced Multidetector-row Computed Tomography in Diagnosis of Obscure Gastrointestinal Bleeding
    Jee Hyun Kim, Jong Pil Im
    The Korean Journal of Gastroenterology.2016; 67(4): 165.     CrossRef
  • 5,993 View
  • 59 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
Spectrum of chronic small bowel diarrhea with malabsorption in Indian subcontinent: is the trend really changing?
Nirav Pipaliya, Meghraj Ingle, Chetan Rathi, Prateik Poddar, Nilesh Pandav, Prabha Sawant
Intest Res 2016;14(1):75-82.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.75
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

This study aimed to document the recent etiological spectrum of chronic diarrhea with malabsorption and also to compare features that differentiate tropical sprue from parasitic infections, the two most common etiologies of malabsorption in the tropics.

Methods

We analyzed 203 consecutive patients with malabsorption. The etiological spectrum and factors that differentiated tropical sprue from parasitic infections were analyzed.

Results

The most common etiology was tropical sprue (n=98, 48.3%) followed by parasitic infections (n=25, 12.3%) and tuberculosis (n=22, 10.8%). Other causes were immunodeficiency (n=15, 7.3%; 12 with human immunodeficiency virus and 3 with hypogammaglobulinemia), celiac disease (n=11, 5.4%), Crohn's disease (n=11, 5.4%), small intestinal bacterial overgrowth (n=11, 5.4%), hyperthyroidism (n=4, 1.9%), diabetic diarrhea (n=4, 1.9%), systemic lupus erythematosus (n=3, 1.4%), metastatic carcinoid (n=1, 0.5%) and Burkitt's lymphoma (n=1, 0.5%). On multivariate analysis, features that best differentiated tropical sprue from parasitic infections were larger stool volume (P=0.009), severe weight loss (P=0.02), knuckle hyperpigmentation (P=0.008), low serum B12 levels (P=0.05), high mean corpuscular volume (P=0.003), reduced height or scalloping of the duodenal folds on endoscopy (P=0.003) and villous atrophy on histology (P=0.04). Presence of upper gastrointestinal (GI) symptoms like bloating, nausea and vomiting predicted parasitic infections (P=0.01).

Conclusions

Tropical sprue and parasitic infections still dominate the spectrum of malabsorption in India. Severe symptoms and florid malabsorption indicate tropical sprue while the presence of upper GI symptoms indicates parasitic infections.

Citations

Citations to this article as recorded by  
  • Inflammatory Bowel Disease in Children
    Asha Jois, George Alex
    Indian Journal of Pediatrics.2024; 91(5): 490.     CrossRef
  • The etiological profile of chronic organic non-bloody diarrhea in India: Emergence of inflammatory bowel disease as a dominant cause
    Prachi Daga, Amarender Singh Puri, Lipika Lipi, Sumit Bhatia, Randhir Sud
    Indian Journal of Gastroenterology.2024;[Epub]     CrossRef
  • The etiological profile of chronic organic non-bloody diarrhea in India: A closer look
    Uday C. Ghoshal, Subhamoy Das, Mahesh K. Goenka
    Indian Journal of Gastroenterology.2024;[Epub]     CrossRef
  • Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia
    Alaullah Sheikh, Brunda Tumala, Tim J. Vickers, John C. Martin, Bruce A. Rosa, Subrata Sabui, Supratim Basu, Rita D. Simoes, Makedonka Mitreva, Chad Storer, Erik Tyksen, Richard D. Head, Wandy Beatty, Hamid M. Said, James M. Fleckenstein
    Nature Communications.2022;[Epub]     CrossRef
  • Acute Bacterial Gastroenteritis
    James M. Fleckenstein, F. Matthew Kuhlmann, Alaullah Sheikh
    Gastroenterology Clinics of North America.2021; 50(2): 283.     CrossRef
  • Clinical, endoscopic, and histological differentiation between celiac disease and tropical sprue: A systematic review
    Pragya Sharma, Vandana Baloda, Gaurav PS Gahlot, Alka Singh, Ritu Mehta, Sreenivas Vishnubathla, Kulwant Kapoor, Vineet Ahuja, Siddhartha Datta Gupta, Govind K Makharia, Prasenjit Das
    Journal of Gastroenterology and Hepatology.2019; 34(1): 74.     CrossRef
  • What makes non-cirrhotic portal hypertension a common disease in India? Analysis for environmental factors
    Ashish Goel, Banumathi Ramakrishna, Uday Zachariah, K.G. Sajith, Deepak K. Burad, Thomas A. Kodiatte, Shyamkumar N. Keshava, K.A. Balasubramanian, Elwyn Elias, C.E. Eapen
    Indian Journal of Medical Research.2019; 149(4): 468.     CrossRef
  • Nutritional Approach in Tropical Sprue Patients
    Stefanie Knebusch Toriello
    Current Tropical Medicine Reports.2018; 5(3): 211.     CrossRef
  • 10,691 View
  • 106 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Case Reports
Refractory pseudomembranous colitis that was treated successfully with colonoscopic fecal microbial transplantation
Jun Young Shin, Eun Jung Ko, Seung Ho Lee, Jong Bum Shin, Shin Il Kim, Kye Sook Kwon, Hyung Gil Kim, Yong Woon Shin, Byoung Wook Bang
Intest Res 2016;14(1):83-88.   Published online January 25, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.83
AbstractAbstract PDFPubReaderePub

Pseudomembranous colitis (PMC) is a nosocomial and opportunistic infection caused by Clostridium difficile. PMC is related to the use of antibiotics leading to intestinal dysbiosis and an overgrowth of C. difficile. Metronidazole or vancomycin is considered to be the standard therapy for the management of PMC. However, PMC has a 15%–30% recurrence rate and can be refractory to standard treatments, resulting in morbidity and mortality. Here we describe a patient who experienced refractory PMC who was treated with fecal microbiota transplantation. A 69-year-old woman was admitted to the hospital with consistent abdominal pain and diarrhea, which had been present for 5 months. She was diagnosed with PMC by colonoscopy and tested positive for C. difficile toxin. Even though she took metronidazole for 10 days, followed by vancomycin for 4 weeks, her symptoms did not improve. Because of her recurrent and refractory symptoms, we decided to perform fecal microbiota transplantation. Fifty grams of fresh feces from a donor were obtained on the day of the procedure, mixed with 500 mL of normal saline, and then filtered. The filtered solution was administered to the patient's colon using a colonoscope. After the procedure, her symptoms rapidly improved and a follow-up colonoscopy showed that the PMC had resolved without recurrence.

Citations

Citations to this article as recorded by  
  • Fecal Microbiota Transplantation for Fulminant Clostridioides Difficile Infection: A Combined Medical and Surgical Case Series
    Ellen J Spartz, Mina Estafanos, Reema Mallick, Wolfganag Gaertner, Victor Vakayil, Cyrus Jahansouz, Rishav Aggarwal, Sayeed Ikramuddin, Alexander Khoruts, James V Harmon
    Cureus.2023;[Epub]     CrossRef
  • Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial
    Jongbeom Shin, Jung-Hwan Lee, Soo-Hyun Park, Boram Cha, Kye Sook Kwon, Hyungkil Kim, Yong Woon Shin
    Biomedicines.2022; 10(10): 2404.     CrossRef
  • The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model
    Qiaomai Xu, Shumeng Zhang, Jiazheng Quan, Zhengjie Wu, Silan Gu, Yunbo Chen, Beiwen Zheng, Longxian Lv, Lanjuan Li
    Applied Microbiology and Biotechnology.2022; 106(19-20): 6689.     CrossRef
  • The gut microbiota and gut disease
    Sasha R. Fehily, Chamara Basnayake, Emily K. Wright, Michael A. Kamm
    Internal Medicine Journal.2021; 51(10): 1594.     CrossRef
  • RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
    Jung Hoon Song, You Sun Kim
    Gut and Liver.2019; 13(1): 16.     CrossRef
  • Clostridium difficile in Asia: Opportunities for One Health Management
    Deirdre A. Collins, Thomas V. Riley
    Tropical Medicine and Infectious Disease.2018; 4(1): 7.     CrossRef
  • Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation
    Yvette H. van Beurden, Max Nieuwdorp, Pablo J. E. J. van de Berg, Chris J. J. Mulder, Abraham Goorhuis
    Therapeutic Advances in Gastroenterology.2017; 10(4): 373.     CrossRef
  • Fecal microbiota transplant in severe and severe-complicatedClostridium difficile: A promising treatment approach
    Monika Fischer, Brian Sipe, Yao-Wen Cheng, Emmalee Phelps, Nicholas Rogers, Sashidhar Sagi, Matthew Bohm, Huiping Xu, Zain Kassam
    Gut Microbes.2017; 8(3): 289.     CrossRef
  • Fecal Microbiota Transplantation for Refractory and RecurrentClostridium difficileInfection: A Case Series of Nine Patients
    Byoung Wook Bang, Jin-Seok Park, Hyung Kil Kim, Yong Woon Shin, Kye Sook Kwon, Hea Yoon Kwon, Ji Hyeon Baek, Jin-Soo Lee
    The Korean Journal of Gastroenterology.2017; 69(4): 226.     CrossRef
  • 6,347 View
  • 49 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Ischemic enteritis with intestinal stenosis
Yorimitsu Koshikawa, Hiroshi Nakase, Minoru Matsuura, Takuya Yoshino, Yusuke Honzawa, Naoki Minami, Satoshi Yamada, Yumiko Yasuhara, Shigehiko Fujii, Toshihiro Kusaka, Dai Manaka, Hiroyuki Kokuryu
Intest Res 2016;14(1):89-95.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.89
AbstractAbstract PDFPubReaderePub

A 75-year-old man was admitted to our hospital with sudden onset of vomiting and abdominal distension. The patient was taking medication for arrhythmia. Computed tomography showed stenosis of the ileum and a small bowel dilatation on the oral side from the region of stenosis. A transnasal ileus tube was placed. Enteroclysis using contrast medium revealed an approximately 6-cm afferent tubular stenosis 10 cm from the terminal ileum and thumbprinting in the proximal bowel. Transanal double-balloon enteroscopy showed a circumferential shallow ulcer with a smooth margin and edema of the surrounding mucosa. The stenosis was so extensive that we could not perform endoscopic balloon dilation therapy. During hospitalization, the patient's nutritional status deteriorated. In response, we surgically resected the region of stenosis. Histologic examination revealed disappearance of the mucosal layer and transmural ulceration with marked fibrosis, especially in the submucosal layer. Hemosiderin staining revealed sideroferous cells in the submucosal layers. Based on the pathologic findings, the patient was diagnosed with ischemic enteritis. The patient's postoperative course was uneventful.

Citations

Citations to this article as recorded by  
  • Myeloid Sarcoma in the Small Intestine
    Masaya Iwamuro, Tomohiro Kamio, Shoichiro Hirata, Katsunori Matsueda, Daisuke Kametaka, Takehiro Tanaka, Seiji Kawano, Motoyuki Otsuka
    Internal Medicine.2025;[Epub]     CrossRef
  • Smooth muscle degeneration of the mesenteric and branching veins causing ischemic enteritis: a case report
    Taiki Sunakawa, Nobuo Ito, Ryo Moriyasu, Nobuya Seki, Daisuke Takeuchi, Kotaro Sasahara
    Surgical Case Reports.2022;[Epub]     CrossRef
  • Ischemic enteritis resulting from polycythemia vera
    Soichi Yagi, Kiyohide Kioka, Yurina Koizumi, Takashi Nakai, Yasuko Kawasaki, Minako Tsutsumi, Naomi Ishii, Tomoaki Yamasaki, Hiroko Nebiki, Kiyoshi Maeda
    Clinical Journal of Gastroenterology.2022; 15(5): 907.     CrossRef
  • Association of decreased variation of coefficient R–R interval with ischemic colitis and small bowel obstruction
    Toshio Arai, Hiroki Yamada, Takeya Edagawa, Satoshi Yoshida, Shigetoshi Hikimoto, Hiromichi Sougawa, Kenichiro Nakachi, Raffaele Serra
    PLOS ONE.2020; 15(2): e0228117.     CrossRef
  • Ileítis isquémica idiopática, con sangrado digestivo oscuro manifiesto
    Gabriel Mosquera-Klinger, Reinaldo Andrés Rincón
    Gastroenterología y Hepatología.2019; 42(7): 439.     CrossRef
  • Small bowel strictures
    Deniz Durmush, Arthur J. Kaffes
    Current Opinion in Gastroenterology.2019; 35(3): 235.     CrossRef
  • Ultrasonographic and histopathological features in 8 cats with fibrotic small intestinal stricture
    Andrew Holloway, Mauro Pivetta, Roberta Rasotto
    Veterinary Radiology & Ultrasound.2019; 60(4): 423.     CrossRef
  • Experience with Balloon Dilatation in Crohn’s and Non-Crohn’s Benign Small-Bowel Strictures: Is There a Difference?
    Akiyoshi Tsuboi, Shiro Oka, Shinji Tanaka, Sumio Iio, Ichiro Otani, Sayoko Kunihara, Ryohei Hayashi, Kazuaki Chayama
    Gastroenterology Research and Practice.2019; 2019: 1.     CrossRef
  • Idiopathic ischaemic ileitis, with overt obscure digestive bleeding
    Gabriel Mosquera-Klinger, Reinaldo Andrés Rincón
    Gastroenterología y Hepatología (English Edition).2019; 42(7): 439.     CrossRef
  • Stenotic Ischemic Enteritis with Concomitant Hepatic Portal Venous Gas and Pneumatosis Cystoides Intestinalis
    Naoto Iwai, Osamu Handa, Yuji Naito, Osamu Dohi, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiko Uchiyama, Takeshi Ishikawa, Tomohisa Takagi, Hideyuki Konishi, Yoshito Itoh
    Internal Medicine.2018; 57(14): 1995.     CrossRef
  • Etiology and long‐term rebleeding of endoscopic ulcerative lesions in the small bowel in patients with obscure gastrointestinal bleeding: A multicenter cohort study
    Tomonori Aoki, Atsuo Yamada, Yoshihiro Hirata, Hirobumi Suzuki, Ayako Nakada, Ryota Niikura, Motoko Seto, Makoto Okamoto, Kazuhiko Koike
    Journal of Gastroenterology and Hepatology.2018; 33(7): 1327.     CrossRef
  • 8,098 View
  • 58 Download
  • 10 Web of Science
  • 11 Crossref
Close layer
Cerebral venous thrombosis in a patient with Crohn's disease
Young-Hak Cho, Min Kyu Chae, Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Il Hyun Baek, Jung Won Jeon, Jun Uk Lim, In Taik Hong, Hye-Jin Ki, Jae Bin Kang
Intest Res 2016;14(1):96-101.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.96
AbstractAbstract PDFPubReaderePub

Patients with inflammatory bowel disease (IBD) have an elevated risk of venous thromboembolism compared with the general population. The most common sites of venous thromboembolism in IBD patients are the deep veins of the legs, the pulmonary system, and portal and mesenteric veins. However, cerebral venous thrombosis is rarely associated with IBD. This report describes a case of cerebral venous thrombosis in a patient with Crohn's disease. A 17-year-old girl, diagnosed 4 years earlier with Crohn's disease, presented with headache and vomiting. Magnetic resonance imaging of the brain with venography showed venous thrombosis in the cortical veins, superior sagittal sinus, right transverse sinus, and right internal jugular vein. The patient immediately started anticoagulation therapy with intravenous heparin infusion followed by daily oral rivaroxaban 10 mg. Follow-up imaging after 2 weeks showed resolution of the thrombosis, with recanalization of the cortical veins, superior sagittal sinus, right transverse sinus, and right internal jugular vein. She continued rivaroxaban therapy for 6 months, and remained well, without neurologic sequelae. A high level of concern for cerebral venous thrombosis may be important when treating active IBD patients, because anticoagulation treatment can prevent fatal complications.

Citations

Citations to this article as recorded by  
  • Cerebral venous thrombosis during relapse of ulcerative colitis: Case report with review of literature
    S. Bouchal, B. Alami, N. Chtaou, M. Abkari, M. Maaroufi, F. Belahsen
    JMV-Journal de Médecine Vasculaire.2021; 46(1): 22.     CrossRef
  • Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review
    Gauruv Bose, Justin Graveline, Vignan Yogendrakumar, Risa Shorr, Dean A Fergusson, Gregoire Le Gal, Jonathan Coutinho, Marcelo Mendonça, Miguel Viana-Baptista, Simon Nagel, Dar Dowlatshahi
    BMJ Open.2021; 11(2): e040212.     CrossRef
  • The Twists and Turns of Diagnosis and Treatment of Pediatric Neuro-Behcet's Disease: A Case Report and Literature Review
    Qiao Zhang, Yizhen Luo, Jianli Zhou, Shaoming Zhou, Zhaoxia Wang
    Frontiers in Pediatrics.2021;[Epub]     CrossRef
  • Recurrent Unprovoked Venous Thrombosis (Cerebral Sinus Thrombosis and Mesenteric Vein Thrombosis) in Young Patient with Crohn’s Disease: A Case Report and Review
    Abdullah Mohammed Albishi, Rafaat Chakik, Ali Saleh Alshamrani
    Case Reports in Gastrointestinal Medicine.2020; 2020: 1.     CrossRef
  • Use of direct oral anticoagulants in cerebral venous thrombosis: a systematic review
    Sen Sheng, Krishina Nalleballe, Naga V. Pothineni, Rohan Sharma, Aliza Brown, Hisham Elkhider, Saritha Ranabothu, Nidhi Kapoor, Kelly-Ann Patrice, Sanjeeva Onteddu
    Blood Coagulation & Fibrinolysis.2020; 31(8): 501.     CrossRef
  • Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review
    Laurent Bertoletti, Ygal Benhamou, Yannick Béjot, Sylvestre Marechaux, Saida Cheggour, Boris Aleil, Nicolas Lellouche, Jean-Guillaume Dillinger, Aurélien Delluc
    Blood Reviews.2018; 32(4): 272.     CrossRef
  • A case of ulcerative colitis presenting with cerebral venous thrombosis
    Junghwan Lee, Sung Wook Hwang, Jinhee Lee, Kyung Hwa Jung, Ha Il Kim, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    Intestinal Research.2018; 16(2): 306.     CrossRef
  • Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location
    Dawid T. Janczak, Malgorzata K. Mimier, Robert D. McBane, Patrick S. Kamath, Benjamin S. Simmons, Dalene M. Bott-Kitslaar, Charles J. Lenz, Emily R. Vargas, David O. Hodge, Waldemar E. Wysokinski
    Mayo Clinic Proceedings.2018; 93(1): 40.     CrossRef
  • Use of Novel Oral Anticoagulant to Treat Pulmonary Thromboembolism in Patient with Ulcerative Colitis Superinfected Cytomegalovirus Colitis
    Seok-Hwan Kim, Sunhee Jang, Yegyu Sung, Jun Kyu Park, Yunjung Park, Jintak Yun, Sang-Bum Kang
    The Korean Journal of Gastroenterology.2017; 70(1): 44.     CrossRef
  • 6,034 View
  • 59 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
Imageses of the Issue
Cutaneous lesions in colorectal carcinoma: a rare presentation
Vinay G Zanwar, Sunil V Pawar, Samit S Jain, Chitra S Nayak, Pravin M Rathi
Intest Res 2016;14(1):102-103.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.102
PDFPubReaderePub
  • 3,959 View
  • 44 Download
Close layer
A large symptomatic jejunal subepithelial tumor treated with endoloop-assisted polypectomy using spiral enteroscopy
Jen-Wei Chou, Ken-Sheng Cheng, Ching-Pin Lin
Intest Res 2016;14(1):104-105.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.104
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Polyp Endotherapy for Multiple Jejunal Lipomas Presenting as Small Bowel Intussusception: “Loop and Let Go Technique”
    Chalapathi R. Achanta, Sudhanva V. Kinhal
    Journal of Digestive Endoscopy.2024; 15(02): 138.     CrossRef
  • Advanced therapy by device-assisted enteroscopy
    Enrique Pérez-Cuadrado Martínez, Enrique Pérez-Cuadrado Robles
    Revista Española de Enfermedades Digestivas.2020;[Epub]     CrossRef
  • A unique case of massive gastrointestinal bleeding
    Akihiko Kida, Koichiro Matsuda, Mitsuru Matsuda, Akito Sakai, Yatsugi Noda
    SAGE Open Medical Case Reports.2017;[Epub]     CrossRef
  • 4,829 View
  • 27 Download
  • 3 Web of Science
  • 3 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP